JDD October 2023 Issue Highlights | Special Topic: Atopic Dermatitis
182121821218212
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl …
The October 2023 issue of the Journal of Drugs in Dermatology (JDD) focuses on atopic dermatitis and features mix of original articles, letters to the editor, and case reports. Among many of the topics explored in this issue are statins for treating actinic porokeratosis, ant venom-based ceramide therapy, the psychosocial burden of skin disease among skin of color consumers, treatment of lichen pl … Continue reading "JDD October 2023 Issue Highlights | Special Topic: Atopic Dermatitis"
With a special focus on aesthetic treatments, check out highlights from the September issue of the Journal of Drugs in Dermatology (JDD) straight from the Editor’s desk:
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for t … 
The various presentations of many dermatologic conditions among various skin types are slowly being elucidated throughout the recent years. These differences present as an issue as it leads to delayed diagnosis, treatment, and poorer quality of life. Herein, JDD authors Susuana Adjei MD, et al. present the characteristics of leukemia cutis in a skin of color patient with diagnosed chronic myel … 
With a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk:
Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com … 
In this brief communication, JDD authors T. Roxana Ghadimi BS, Michael J. Martinez BS, and Evan A. Rieder MD present self-reported long-term, remote side effects to isotretinoin that dermatologists must be aware of.
INTRODUCTION
Isotretinoin is considered the gold standard treatment for severe nodulocystic acne, though it has been the subject of controversy in the media for concerns relate … 